279 related articles for article (PubMed ID: 33239388)
1. Systemic cancer therapy with engineered adenovirus that evades innate immunity.
Atasheva S; Emerson CC; Yao J; Young C; Stewart PL; Shayakhmetov DM
Sci Transl Med; 2020 Nov; 12(571):. PubMed ID: 33239388
[TBL] [Abstract][Full Text] [Related]
2. Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo.
Ma J; Duffy MR; Deng L; Dakin RS; Uil T; Custers J; Kelly SM; McVey JH; Nicklin SA; Baker AH
PLoS Pathog; 2015 Feb; 11(2):e1004673. PubMed ID: 25658827
[TBL] [Abstract][Full Text] [Related]
3. Structural Model for Factor X Inhibition of IgM and Complement-Mediated Neutralization of Adenovirus.
Wagner N; Shayakhmetov DM; Stewart PL
Viruses; 2023 Jun; 15(6):. PubMed ID: 37376642
[TBL] [Abstract][Full Text] [Related]
4. Cryo-EM structure of human adenovirus D26 reveals the conservation of structural organization among human adenoviruses.
Yu X; Veesler D; Campbell MG; Barry ME; Asturias FJ; Barry MA; Reddy VS
Sci Adv; 2017 May; 3(5):e1602670. PubMed ID: 28508067
[TBL] [Abstract][Full Text] [Related]
5. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.
Short JJ; Rivera AA; Wu H; Walter MR; Yamamoto M; Mathis JM; Curiel DT
Mol Cancer Ther; 2010 Sep; 9(9):2536-44. PubMed ID: 20736345
[TBL] [Abstract][Full Text] [Related]
6. Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.
Zhang Z; Krimmel J; Zhang Z; Hu Z; Seth P
Hum Gene Ther; 2011 Sep; 22(9):1137-42. PubMed ID: 21480822
[TBL] [Abstract][Full Text] [Related]
7. Genetic strategy to decrease complement activation with adenoviral therapies.
Gentile CM; Borovjagin AV; Richter JR; Jani AH; Wu H; Zinn KR; Warram JM
PLoS One; 2019; 14(4):e0215226. PubMed ID: 31026285
[TBL] [Abstract][Full Text] [Related]
8. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.
Alba R; Bradshaw AC; Parker AL; Bhella D; Waddington SN; Nicklin SA; van Rooijen N; Custers J; Goudsmit J; Barouch DH; McVey JH; Baker AH
Blood; 2009 Jul; 114(5):965-71. PubMed ID: 19429866
[TBL] [Abstract][Full Text] [Related]
9. A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.
Gu L; Krendelchtchikova V; Krendelchtchikov A; Oster RA; Fujihashi K; Matthews QL
Virol J; 2014 Jun; 11():112. PubMed ID: 24935650
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses.
Bradshaw AC; Coughlan L; Miller AM; Alba R; van Rooijen N; Nicklin SA; Baker AH
J Control Release; 2012 Dec; 164(3):394-402. PubMed ID: 22626939
[TBL] [Abstract][Full Text] [Related]
11. Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon.
Xue C; Tian X; Li X; Zhou Z; Su X; Zhou R
Virus Res; 2014 Apr; 183():67-74. PubMed ID: 24518297
[TBL] [Abstract][Full Text] [Related]
12. Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX.
Stepanenko AA; Chekhonin VP
Virus Res; 2018 Sep; 257():40-51. PubMed ID: 30125593
[TBL] [Abstract][Full Text] [Related]
13. Human full-length coagulation factor X and a GLA domain-derived 40-mer polypeptide bind to different regions of the adenovirus serotype 5 hexon capsomer.
Sumarheni S; Hong SS; Josserand V; Coll JL; Boulanger P; Schoehn G; Fender P
Hum Gene Ther; 2014 Apr; 25(4):339-49. PubMed ID: 24512117
[TBL] [Abstract][Full Text] [Related]
14. Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity.
Krutzke L; Prill JM; Engler T; Schmidt CQ; Xu Z; Byrnes AP; Simmet T; Kreppel F
J Control Release; 2016 Aug; 235():379-392. PubMed ID: 27302248
[TBL] [Abstract][Full Text] [Related]
15. Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates.
Bots STF; Kemp V; Cramer SJ; van den Wollenberg DJM; Hornsveld M; Lamfers MLM; van der Pluijm G; Hoeben RC
Hum Gene Ther; 2022 Mar; 33(5-6):275-289. PubMed ID: 34861769
[TBL] [Abstract][Full Text] [Related]
16. Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.
Shashkova EV; May SM; Doronin K; Barry MA
Mol Ther; 2009 Dec; 17(12):2121-30. PubMed ID: 19755961
[TBL] [Abstract][Full Text] [Related]
17. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation.
Schoggins JW; Nociari M; Philpott N; Falck-Pedersen E
J Virol; 2005 Sep; 79(18):11627-37. PubMed ID: 16140740
[TBL] [Abstract][Full Text] [Related]
18. Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.
Bruder JT; Chen P; Semenova E; Thomas CA; Konovalova S; Ekberg G; Ettyreddy D; McVey D; Gall JG; King CR; Brough DE
J Virol; 2013 Sep; 87(17):9661-71. PubMed ID: 23824800
[TBL] [Abstract][Full Text] [Related]
19. Small-size recombinant adenoviral hexon protein fragments for the production of virus-type specific antibodies.
Pacesa M; Hendrickx R; Bieri M; Flatt JW; Greber UF; Hemmi S
Virol J; 2017 Aug; 14(1):158. PubMed ID: 28821267
[TBL] [Abstract][Full Text] [Related]
20. Lung macrophage scavenger receptor SR-A6 (MARCO) is an adenovirus type-specific virus entry receptor.
Stichling N; Suomalainen M; Flatt JW; Schmid M; Pacesa M; Hemmi S; Jungraithmayr W; Maler MD; Freudenberg MA; Plückthun A; May T; Köster M; Fejer G; Greber UF
PLoS Pathog; 2018 Mar; 14(3):e1006914. PubMed ID: 29522575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
